Universal Health International Group Holding Limited (2211) released its unaudited interim results for the six months ended 31 December 2025. The company recorded revenue of RMB266.80 million, marking a 39.50% decrease compared to RMB441.20 million in the same period last year. Loss for the period narrowed year-on-year to RMB6.10 million from RMB7.70 million. Adjusted EBITDA saw an improvement from negative RMB1.10 million in the prior year period to RMB3.30 million.
During the period, retail segment revenue stood at RMB90.90 million, a decrease from last year's RMB118.90 million. The company had 115 retail stores in total. Distribution segment revenue decreased to RMB175.90 million from RMB322.30 million in the previous year, with the number of active distributors reduced to 660, compared with 952 last year.
Overall gross profit was RMB47.40 million, representing a 32.70% year-on-year decrease. Gross margin, however, rose from 15.90% last year to 17.80%. Operating loss was RMB3.40 million, an improvement of RMB4.50 million from the previous year’s figure. Basic loss per share was RMB6.21 cents, improving by RMB3.79 cents on a restated basis.
As of 31 December 2025, the company reported net current assets of RMB65.70 million. Net cash flows from operating activities were RMB21.10 million, up from RMB8.70 million in the same period last year. The board resolved not to declare an interim dividend for the reporting period.
According to the announcement, the company intends to focus on strategic initiatives, including specialized product offerings and integrated online-offline channels, to enhance its competitiveness in China’s healthcare market. It will continue to refine its pharmacy services, distribution system, and associated membership programs while maintaining prudent financial management and cost controls.
Comments